TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: What Should be the Best Physiotherapy Early After Stroke ?
Brief Summary: This study is designed to observe the respective effects of 2 types of physiotherapy early after a cerebral stroke. The hypothesis is that an intensive physiotherapy early delivered (Day 2 to D15) after a stroke could induce faster motor control recovery than a conservative physiotherapy aiming at preventing complications.


Options:
A: Arm Label: Trunk training; Type: EXPERIMENTAL; Interventions: Other: Trunk training | Arm Label: Cognitive exercises; Type: SHAM_COMPARATOR; Interventions: Other: Cognitive exercises | Intervention Type: OTHER; Name: Trunk training; Assigned to Arm(s): Trunk training | Intervention Type: OTHER; Name: Cognitive exercises; Assigned to Arm(s): Cognitive exercises
B: Arm Label: STARFISH intervention; Type: EXPERIMENTAL; Interventions: Behavioral: STARFISH intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: STARFISH intervention; Assigned to Arm(s): STARFISH intervention
C: Arm Label: Stroke Management Program (SMP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stroke Management Program (SMP) | Arm Label: Stroke Monitoring Program (SMonP); Type: EXPERIMENTAL; Interventions: Behavioral: Stroke Monitoring Program (SMonP) | Arm Label: Stroke Supplementary Program (SSP); Type: EXPERIMENTAL; Interventions: Behavioral: Stroke Supplementary Program (SSP) | Intervention Type: BEHAVIORAL; Name: Stroke Management Program (SMP); Assigned to Arm(s): Stroke Management Program (SMP) | Intervention Type: BEHAVIORAL; Name: Stroke Monitoring Program (SMonP); Assigned to Arm(s): Stroke Monitoring Program (SMonP) | Intervention Type: BEHAVIORAL; Name: Stroke Supplementary Program (SSP); Assigned to Arm(s): Stroke Supplementary Program (SSP)
D: Arm Label: group 1: standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: standard physiotherapy | Arm Label: group 2: experimental physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: experimental physiotherapy | Intervention Type: PROCEDURE; Name: standard physiotherapy; Assigned to Arm(s): group 1: standard physiotherapy | Intervention Type: PROCEDURE; Name: experimental physiotherapy; Assigned to Arm(s): group 2: experimental physiotherapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Training for Patients With Schizophrenia
Brief Summary: This research on cognitive training addresses the following questions:

1. Does cognitive training lead to improved cognition, functional abilities, psychiatric symptoms, treatment adherence, or quality of life in patients with psychoses?
2. What are the neurocognitive and non-cognitive factors that predict good outcomes following cognitive rehabilitation? In addition to verbal learning and memory, immediate verbal memory, vigilance, and executive functioning, the cognitive training intervention attempted to improve prospective memory ability (i.e., the ability to remember to do things in the future, such as take medications or attend a doctor's appointment).


Options:
A: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A
B: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care
C: Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Training | Arm Label: Standard Pharmacotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training
D: Arm Label: Supported Employment Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported Employment | Arm Label: Thinking Skills for Work; Type: EXPERIMENTAL; Interventions: Behavioral: Thinking Skills for Work Program | Intervention Type: BEHAVIORAL; Name: Thinking Skills for Work Program; Assigned to Arm(s): Thinking Skills for Work | Intervention Type: BEHAVIORAL; Name: Supported Employment; Assigned to Arm(s): Supported Employment Only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Brief Personalized Feedback Intervention in University Students
Brief Summary: Excessive alcohol consumption in university students continues for be a serious public health concern with a variety of negative consequences. There have been a number of different brief interventions developed to address this issue among university students. The current project will add to this literature by evaluating the use of a personalized feedback intervention (www.CheckYourDrinkingU.net; CYDU). Specifically, this trial will examine whether providing access to the CYDU will result in short-term reductions in drinking. This issue is important as use of these interventions is not a mandatory requirement for university students so the issue is whether making materials of this type available leads to any reductions in risky drinking. It is hypothesized that students provided access to the CYDU will display greater reductions in drinking at a six-week follow-up as compared to students who were not provided access to the CYDU.


Options:
A: Arm Label: Electronic monitor + no text message; Type: PLACEBO_COMPARATOR; Interventions: Device: Electronic + no text message | Arm Label: Electronic monitor + Text message; Type: EXPERIMENTAL; Interventions: Device: Electronic monitor + text messages | Intervention Type: DEVICE; Name: Electronic + no text message; Assigned to Arm(s): Electronic monitor + no text message | Intervention Type: DEVICE; Name: Electronic monitor + text messages; Assigned to Arm(s): Electronic monitor + Text message
B: Arm Label: Mobile Phone Condition; Type: EXPERIMENTAL; Interventions: Behavioral: Personalized Real-Time Intervention for Stabilizing Mood | Arm Label: Paper-and-pencil condition; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Personalized Real-Time Intervention for Stabilizing Mood | Intervention Type: BEHAVIORAL; Name: Personalized Real-Time Intervention for Stabilizing Mood; Assigned to Arm(s): Mobile Phone Condition, Paper-and-pencil condition
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Check Your Drinking University version | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Check Your Drinking University version; Assigned to Arm(s): Intervention
D: Arm Label: MONARCA; Type: ACTIVE_COMPARATOR; Interventions: Device: MONARCA | Arm Label: NON-MONARCA; Type: PLACEBO_COMPARATOR; Interventions: Device: NON-MONARCA | Intervention Type: DEVICE; Name: MONARCA; Assigned to Arm(s): MONARCA | Intervention Type: DEVICE; Name: NON-MONARCA; Assigned to Arm(s): NON-MONARCA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Wireless Technology in Clinical Practice: Does Feedback of Daily Walking Activity Improve Walking Outcomes of Individuals Receiving Rehabilitation Post-stroke?
Brief Summary: Regaining independent walking is the top priority for individuals recovering from stroke. Thus, physical rehabilitation post-stroke should focus on improving walking function and endurance. However, the amount of walking completed by individuals with stroke attending rehabilitation is far below that required for independent community ambulation. There has been increased interest in accelerometer-based monitoring of walking post-stroke. Walking monitoring could be integrated within the goal-setting process for those with ambulation goals in rehabilitation. The purpose of this study is to determine the effect of accelerometer-based feedback of daily walking activity during rehabilitation on the frequency and duration of walking post-stroke.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
B: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care
C: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
D: Arm Label: Feedback group; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of daily walking activity | Arm Label: No-feedback group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feedback of daily walking activity; Assigned to Arm(s): Feedback group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Wireless Technology in Clinical Practice: Does Feedback of Daily Walking Activity Improve Walking Outcomes of Individuals Receiving Rehabilitation Post-stroke?
Brief Summary: Regaining independent walking is the top priority for individuals recovering from stroke. Thus, physical rehabilitation post-stroke should focus on improving walking function and endurance. However, the amount of walking completed by individuals with stroke attending rehabilitation is far below that required for independent community ambulation. There has been increased interest in accelerometer-based monitoring of walking post-stroke. Walking monitoring could be integrated within the goal-setting process for those with ambulation goals in rehabilitation. The purpose of this study is to determine the effect of accelerometer-based feedback of daily walking activity during rehabilitation on the frequency and duration of walking post-stroke.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Tele-Rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Tele-rehabilitation | Intervention Type: OTHER; Name: Tele-rehabilitation; Assigned to Arm(s): Tele-Rehabilitation
B: Arm Label: Feedback group; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of daily walking activity | Arm Label: No-feedback group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feedback of daily walking activity; Assigned to Arm(s): Feedback group
C: Arm Label: Control - usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Manual; Type: ACTIVE_COMPARATOR; Interventions: Other: 'The Healthy Brain Rehabilitation Manual', Procedure: Usual care | Arm Label: Manual + pedometer, 1; Type: ACTIVE_COMPARATOR; Interventions: Other: 'The Healthy Brain Rehabilitation Manual', Device: Pedometer, Procedure: Usual care, Behavioral: Telephone follow-up | Arm Label: Manual + pedometer, 2; Type: ACTIVE_COMPARATOR; Interventions: Other: 'The Healthy Brain Rehabilitation Manual', Device: Pedometer, Procedure: Usual care, Behavioral: Telephone follow-up | Intervention Type: OTHER; Name: 'The Healthy Brain Rehabilitation Manual'; Assigned to Arm(s): Manual, Manual + pedometer, 1, Manual + pedometer, 2 | Intervention Type: DEVICE; Name: Pedometer; Assigned to Arm(s): Manual + pedometer, 1, Manual + pedometer, 2 | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Manual, Manual + pedometer, 1, Manual + pedometer, 2 | Intervention Type: BEHAVIORAL; Name: Telephone follow-up; Assigned to Arm(s): Manual + pedometer, 1, Manual + pedometer, 2
D: Arm Label: Memory Training Program; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healthy Lifestyle Training Program; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Lifestyle Training Program | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyle Training Program; Assigned to Arm(s): Healthy Lifestyle Training Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Treatment With Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular Dystrophy
Brief Summary: Duchenne muscular dystrophy (DMD), the most common muscular dystrophy, leads to skeletal and cardiac muscle damage. Treatment of pulmonary complications has improved survival; however, heart muscle disease or cardiomyopathy has emerged as a leading cause of death, typically by the third decade. Although myocardial changes begin early, clinically significant heart disease is rarely detected in the first decade of life. Consequently, DMD cardiomyopathy frequently goes unrecognized (and untreated) until advanced (and irreversible).

Current DMD cardiovascular care guidelines recommend beta-blockers and angiotensin converting enzyme inhibitors (ACEIs) when decreased ejection fraction (EF) is noted by echocardiography (echo); however, this strategy has not significantly improved outcomes. Our team has recently made a breakthrough in a mouse study, showing in a model that causes the same heart muscle disease in humans with DMD adding an old medicine traditionally used for high blood pressure and late-stage heart failure can actually prevent heart muscle damage. Because of this drug's proven safety in both children and adults, it is ready to be studied immediately in an RCT in patients with DMD to hopefully show, as we did in mice, that we can prevent the devastating consequences of heart muscle damage.


Options:
A: Arm Label: eplerenone; Type: ACTIVE_COMPARATOR; Interventions: Drug: eplerenone | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: eplerenone; Assigned to Arm(s): eplerenone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): sugar pill
B: Arm Label: Lisinopril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril | Arm Label: Losartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Losartan | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): Losartan | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Lisinopril
C: Arm Label: Continuous regimen; 6mg/kg once weekly; Type: EXPERIMENTAL; Interventions: Drug: GSK2402968, Drug: matched placebo | Arm Label: Intermittent regimen; 6mg/kg twice weekly; Type: EXPERIMENTAL; Interventions: Drug: GSK2402968, Drug: matched placebo | Intervention Type: DRUG; Name: GSK2402968; Assigned to Arm(s): Continuous regimen; 6mg/kg once weekly, Intermittent regimen; 6mg/kg twice weekly | Intervention Type: DRUG; Name: matched placebo; Assigned to Arm(s): Continuous regimen; 6mg/kg once weekly, Intermittent regimen; 6mg/kg twice weekly
D: Arm Label: Implantable Counterpulsation Therapy; Type: EXPERIMENTAL; Interventions: Device: C-Pulse™ (Implantable Counterpulsation Therapy) | Intervention Type: DEVICE; Name: C-Pulse™ (Implantable Counterpulsation Therapy); Assigned to Arm(s): Implantable Counterpulsation Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis
Brief Summary: This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 \[NCT01519791\]. Subjects entering this study RA0055 Period 2 achieved sustained Low Disease Activity at Week 52 in study RA0055 Period 1.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group B
B: Arm Label: 1-M : Maintenance; Type: ACTIVE_COMPARATOR; Interventions: Drug: DMARD maintenance | Arm Label: 2 -S : Spacing of TNF-blocker injections; Type: EXPERIMENTAL; Interventions: Drug: progressive spacing of TNF-blocker injections | Intervention Type: DRUG; Name: progressive spacing of TNF-blocker injections; Assigned to Arm(s): 2 -S : Spacing of TNF-blocker injections | Intervention Type: DRUG; Name: DMARD maintenance; Assigned to Arm(s): 1-M : Maintenance
C: Arm Label: CZP 200 mg Q2W + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX) | Arm Label: CZP 200 mg Q4W + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX) | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo + Methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol + Methotrexate (MTX); Assigned to Arm(s): CZP 200 mg Q2W + Methotrexate, CZP 200 mg Q4W + Methotrexate | Intervention Type: BIOLOGICAL; Name: Placebo + Methotrexate (MTX); Assigned to Arm(s): Placebo + Methotrexate
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study to Investigate the Efficacy and Safety of SYR-322 When Used in Combination With Insulin Preparation in Subjects With Type 2 Diabetes in Japan
Brief Summary: To determine the efficacy and safety of SYR-322 (alogliptin) 25-mg, once daily (QD), in patients with diabetes when used in combination with insulin.


Options:
A: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
B: Arm Label: SYR-322 (Alogliptin) QD; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Arm Label: Insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): SYR-322 (Alogliptin) QD | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Care Rehabilitation After Acute Coronary Syndrome
Brief Summary: Cardiac rehabilitation is an individual adapted multidisciplinary intervention for people suffering from Heart Disease. It involves;

* Dietary counseling,
* Exercise training,
* Psychosocial support,
* Physician
* smoking cessation
* Patient education

The purpose is quick and complete recovery and to reduce the chance of recurrence.

In Denmark people admitted with Acute Cardiac Disease is referred to a course of hospital based cardiac rehabilitation at discharge.

The Danish Municipal Reform of 2007 changed the responsibility of rehabilitation from the Regions, who runs the hospitals, to the municipalities.

Shared care is in this setting that elements of treatment are completed different places in Health Care.

The aim of this study is:

* to establish a shared care model for Cardiac rehabilitation following admission with Acute Coronary Syndrome and
* to compare this model to the existing hospital based cardiac rehabilitation after admission with Acute Coronary Syndrome.

Primary outcome is participation in cardiac rehabilitation.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2
B: Arm Label: Hospital-based; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Shared care Model; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Shared Care model | Intervention Type: BEHAVIORAL; Name: Shared Care model; Assigned to Arm(s): Shared care Model
C: Arm Label: Family-Centered Empowerment Model; Type: EXPERIMENTAL; Interventions: Other: Family-centered empowerment model | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Family-centered empowerment model; Assigned to Arm(s): Family-Centered Empowerment Model | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Aerobic Exercise Program; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Program | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Program; Assigned to Arm(s): Aerobic Exercise Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Brief Summary: There is growing but limited information on the long term clinical status of aHUS patients who have previously received or are continuing to receive treatment with eculizumab. This study is designed to collect clinical data that will provide insight into the long-term outcomes of patients with aHUS.


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: OMS721; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Intervention Type: BIOLOGICAL; Name: OMS721; Assigned to Arm(s): OMS721
C: N/A
D: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): Eculizumab

Answer: C